A roundtable discussion of aromatase inhibitors as therapy for breast cancer.
Allred, D Baum, M Buzdar, A Carlson, R Dowsett, M Elledge, R Gradishar, W Grana, G Mamounas, E
Allred, D
Baum, M
Buzdar, A
Carlson, R
Dowsett, M
Elledge, R
Gradishar, W
Grana, G
Mamounas, E
Citations
Altmetric:
Abstract
This article summarizes the conclusions of a meeting of diverse breast cancer experts who discussed issues, controversies, and new clinical trial results relevant to the use of aromatase inhibitors for treating postmenopausal women with breast cancer. The new generation of aromatase inhibitors (anastrozole, letrozole, exemestane) have largely replaced megestrol acetate as a second-line therapy in postmenopausal women with hormone-responsive advanced breast cancer. In addition, anastrozole and letrozole have been shown to be superior to tamoxifen for first-line therapy. Finally, recent results suggest that anastrozole may be superior to tamoxifen as adjuvant therapy for early stage disease in postmenopausal women with hormone-responsive disease.
Affiliation
Description
Date
2003
Publisher
Collections
Keywords
Hormonal Anticancerous Agents
Breast Cancer
Breast Cancer
Type
Article
Citation
A roundtable discussion of aromatase inhibitors as therapy for breast cancer., 9 (3):213-22 Breast J